Topics

Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?

2017-05-08 12:49:29 | BioPortfolio

Summary

It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards vaccine unrelated pathogens, resulting in excess mortality(Aaby, Kollmann, & Benn, 2014) A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced risk of atopic dermatitis (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016).

This register based observational study aims to extend the existing knowledge on non-specific effects of non-live vaccines by testing the above finding, that delayed vaccination with Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b (DTaP-IPV-Hib) is associated with lower risk of developing atopic dermatitis before 1 year of age in the Danish birth cohorts from 1997-2012.

Description

It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called non-specific effects with the potential to affect resistance towards vaccine unrelated pathogens, resulting in excess mortality and morbidity(Aaby et al., 2014). These immunomodifying effects may affect development of atopic dermatitis through increased immunological sensitivity(Nilsson, Gruber, Granstrom, Bjorksten, & Kjellman, 1998). A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced eczema (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016). The present study aims to test the above finding and investigate the effect of timeliness of vaccination with DTaP-IPV-Hib (with or without PCV) on development of atopic dermatitis before 1 year of age among Danish children born between 1997 and 2012. From 1997 to 2012 children in Denmark were scheduled to receive the 1st, 2nd, and 3rd dose of DTaP-IPV-Hib at 3, 5, and 12 months respectively.

Primary investigation:

Research question 1.a Is delayed vaccination with the first dose of DTaP-IPV-Hib (vaccination at or after 4 months of age) associated with a reduced risk of development of atopic dermatitis from 4 months and until but not including 12 months of age compared with receiving the first dose of DTaP-IPV-Hib before 4 months of age?

Secondary investigations:

Research question 1.b Among children with a timely 1st dose of DTaP-IPV-Hib (vaccination before 4 months of age), is delayed vaccination with the second dose of DTaP-IPV-Hib (vaccination at or after 6 months of age) associated with a reduced risk of development of atopic dermatitis from 6 months and until but not including 12 months of age compared with receiving the second dose of DTaP-IPV-Hib before 6 months of age?

Research question 2. Is receipt of DTaP-IPV-Hib associated with development of atopic dermatitis from 3 months and until but not including 8 months of age compared with being unvaccinated?

Data assessment Information on development of atopic dermatitis and vaccination status is assessed at baseline (which is 4 months of age (research question 1.a.),6 months of age (research question 1.b.) and 3 months of age (research question 2.)) and through follow up (until 1 year of age). Confounder information is assessed at 3 months of age for all analyses.

Development of atopic dermatitis is assessed according to an algorithm described in detail under "9. Outcome measures", which uses information on prescriptions and hospitalizations up until one year after the last age of outcome assessment (1 year of age in this study) to confirm a case. Children must therefore be alive and living in Denmark until 2 years of age representative of age at end of follow-up plus 1 year.

The Danish national registers contains individual-level information on a broad range of health and social factors. Every child born in Denmark receives a unique personal identification number (ID) at birth, which follows the individual through life. Using the ID it is possible to link information from the different registers at an individual level.

Confounders:

We will seek to retain information on potential confounders from the Danish registers. Potential confounders will be assessed at 3 months of age and included in the adjusted analyses.

From the Danish Civil Registration System we will obtain information on sex, season of birth, death, emigration, parental identity, sibling's identity and exact address. We will use information on parental identity to link every child to its parents and obtain information on parents' origin of birth. We will obtain information on single parenthood and the number of children in the household. We will furthermore derive information on population density based on information on the municipality in which the child lives. We will use information on parental and sibling's identity to link information on family history of atopic dermatitis to the child. Atopic dermatitis is categorized according to the algorithm described in detail under "9. Outcome measures".

The variables; caesarean section, preterm birth, birthweight, and maternal smoking during pregnancy is obtained from the Danish Medical Birth Register, which contains information on all live and stillbirths in Denmark. Antibiotic use is recorded in the Danish National Prescription Register. Information on chronic disease is obtained from in the Danish national patient registry. Household income is obtained from the Danish registers on personal income and transfer payment.

Maternal highest education is obtained from the Danish education registers.

The dataset is expected to contain close to complete information on confounders. Hence, it is expected that children with missing confounder information constitute an ignorable proportion of the complete study population, wherefore we will only conduct complete case analyses.

Statistical model for research question 1.a +1.b; investigation of the effect of timing of vaccination.

For investigation of the effect of timing of the first and second dose of DTaP-IPV-Hib with or without PCV, we will use a Binary regression model to estimate the adjusted relative risk of developing atopic dermatitis from baseline (age for categorized timely vaccination) until one year of age, among delayed vaccinated compared to timely vaccinated children. The analysis will include all abovementioned potential confounders. Absolute risk differences will be reported if relevant.

Intended subgroup and sensitivity analysis for the primary investigation (research question 1.a) The following presents a priory identified relevant subgroup and sensitivity analyses. If relevant, we will furthermore include additional analysis with the aim to pursue potential tendencies revealed in the data analysis.

1. Sex differential effect Data will be analyzed for effect modification by sex because of evidence of sex-differential non-specific effects of vaccines (Aaby et al., 2014) and also sex-differential atopic sensitization associated with delayed vaccination (Kiraly et al., 2016).

2. Further subgroup analyses

- Effect modification by PCV vaccination. PCV was enrolled into the Danish vaccination schedule during the years of this investigation. Hence, it will be investigated if potential NSEs of DTaP-IPV-Hib vary according to receipt of PCV.

- Exploratory analysis of effect modification.

- Subgroup analysis, which only includes first born children; Parents of children with older siblings may be more familiar with AD, which may result in a less frequent health care seeking behavior. Parents of children with older siblings, who have had AD themselves, may further have prescription medicines in the home from treatment of prior cases of AD among the siblings. Hence, cases of AD categorized based on disease specific prescriptions may be misclassified if the parents do not get a new prescription for that child.

3. Sensitivity analyses

- Sensitivity analysis to investigate if the results are affected by inclusion of children with no DTaP-IPV-Hib before 1 year of age.

- Investigation of reverse causation: A Cox regression will be conducted to investigate if presence of atopic dermatitis is associated with subsequent delayed vaccination.

- Inclusion of negative control outcome/exposure; In similar studies, it has been suspected that there may be a risk of ascertainment bias, whereby parents of children who are delayed vaccinated, represent parents with a general lower health care seeking behavior, which could result in lower levels of AD diagnosis among their children. In order to accommodate this potential unmeasured confounder, we will seek to identify a relevant negative control exposure or outcome, which will help indicate the strength of a potential interference from this unmeasured confounder.

Statistical model for investigation of research question 2; investigation of the effect of being vaccinated with DTaP-IPV-Hib with or without PCV compared with being non-vaccinated.

For investigation of the effect of being vaccinated with DTaP-IPV-Hib compared with being non-vaccinated we will use a Cox proportional hazards regression with age as the underlying time to estimate the adjusted HR of developing atopic dermatitis among children vaccinated with DTaP-IPV-Hib compared with unvaccinated children. Vaccination status will be assessed from time of scheduled vaccination (3 months of age) and set as a time dependent variable with the categories unvaccinated and vaccinated.

As vaccination status is included as a time dependent variable, the group of unvaccinated children will inherently become smaller with time as they get vaccinated. In order to assure sufficient group sizes, children will only be followed until 8 months of age.

The model will include all identified potential confounding factors listed above. All co-variates will be included as fixed variables and assessed at baseline (3 months of age).

Proportional hazard assumption will be examined.

Sensitivity analysis for the Cox regression

1) Delayed diagnosis Atopic dermatitis does not become apparent until the child has scratched the affected skin. Furthermore, it may take weeks to months before the parents become aware that this is not something which is passing, and bring the child to a doctor. Therefore, it is very likely that actual onset of AD is weeks/months prior to date of diagnosis by the healthcare professionals or receipt of disease specific prescriptions. Due to this delay, there is a risk of differential misclassification, whereby cases of AD may be falsely ascribed to the vaccinated exposure group. As a result, we will conduct a sensitivity analysis, whereby the date for onset of AD accounts for this delay and is set prior to onset according to the AD algorithm. We will contact primary health care facilities in order to gain expert insight on approximate delay from onset of symptoms to receipt of prescription medicines or referral to a hospital.

Study Design

Conditions

Atopic Dermatitis

Intervention

RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib, RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib, RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated

Status

Completed

Source

Bandim Health Project

Results (where available)

View Results

Links

Published on BioPortfolio: 2017-05-08T12:49:29-0400

Clinical Trials [1145 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP HB PRP~T Combined Vaccine in Filipino Infants

DTaP-HB-PRP~T combined vaccine is being developed in order to comply with expanding programs for immunization in infancy, while offering the benefit of a reduced number of injections, and ...

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

Subjects will be recruited and divided into 3 groups:(1)combined immunization of Sabin-IPV and DTaP, (2) Sabin-IPV only and (3) DTaP only. After finishing the two basic vaccine EPI proced...

Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine

The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362...

Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants

This is a follow-up of Study A3L10. Immunogenicity - To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP~T or PENTAXIM™ and ENG...

Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP

Eligible,healthy infants will be recruited and divided into 3 groups:(1)combined immunization of sIPV and DTaP group, (2) sIPV group and (3) DTaP group. After completing the two basic vacc...

PubMed Articles [7048 Associated PubMed Articles listed on BioPortfolio]

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.

In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and...

Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.

In April 2016, an emergency vaccination campaign using one dose of Oral Cholera Vaccine (OCV) was organized in response to a cholera outbreak that started in Lusaka in February 2016. In December 2016,...

Human papillomavirus (HPV) and influenza vaccine behavior among Muslim women in the United States.

In this study, we examined vaccination behaviors-single dose human papillomavirus (HPV) vaccination, triple dose HPV vaccination, and influenza vaccination-among Muslim women residing in the United St...

Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

In 2013, Turkey introduced one-dose universal varicella vaccination (UVV) at 12 months of age. Inclusion of a second dose is being considered.

Successful Vaccination with Tdap after Adverse Reaction to DTaP or DT in Pediatric Patients.

Medical and Biotech [MESH] Definitions

Group activities directed against VACCINATION.

Rate of VACCINATION as defined by GEOGRAPHY and or DEMOGRAPHY.

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

Refusal to receive VACCINATION.

A treatment schedule in which the total dose of radiation is divided into large doses.

More From BioPortfolio on "Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?"

Quick Search

Relevant Topics

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Searches Linking to this Trial